The Non Alcoholic Fatty Liver Disease (NAFLD) drugs in development market research report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non Alcoholic Fatty Liver Disease (NAFLD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued products.

GlobalData tracks 157 drugs in development for Non Alcoholic Fatty Liver Disease (NAFLD) by 126 companies/universities/institutes. The top development phase for Non Alcoholic Fatty Liver Disease (NAFLD) is preclinical with 63 drugs in that stage. The Non Alcoholic Fatty Liver Disease (NAFLD) pipeline has 148 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market are: Pfizer, Eli Lilly and Co and Gilead Sciences.

The key targets in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market include Glucagon Like Peptide 1 Receptor (GLP1R), Glucagon Receptor (GL R or GCGR), and Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB).

The key mechanisms of action in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline product include Glucagon Like Peptide 1 Receptor (GLP1R) Agonist with eight drugs in Phase II. The Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products include nine routes of administration with the top ROA being Oral and 15 key molecule types in the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline products market including Small Molecule, and Synthetic Peptide.

Non Alcoholic Fatty Liver Disease (NAFLD) overview

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

For a complete picture of Non Alcoholic Fatty Liver Disease (NAFLD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.